Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial

Journal of Hepatology

Volumn 65, Issue 2, 2016, Pages 369-376

  Cui, Jeffrey ^a   Philo, Len ^b   Nguyen, Phirum ^a   Hofflich, Heather ^a   Hernandez, Carolyn ^a   Bettencourt, Ricki ^a   Richards, Lisa ^a   Salotti, Joanie ^a   Bhatt, Archana ^a   Hooker, Jonathan ^a   Haufe, William ^a   Hooker, Catherine ^a   Brenner, David A ^a   Sirlin, Claude B ^a   Loomba, Rohit ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^c San Diego Integrated NAFLD Research Consortium (SINC)   (United States)

Author keywords

Biomarker; Fat mapping; Fibrosis; Hepatic steatosis; Imaging; Lipid lowering therapy; Magnetic resonance elastography; MRI proton density fat fraction (PDFF); NAFLD; Non alcoholic steatohepatitis; Non invasive assessment; Sitagliptin

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA 2 MACROGLOBULIN; ASPARTATE AMINOTRANSFERASE; FATTY ACID; HEMOGLOBIN A1C; HYALURONIC ACID; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SITAGLIPTIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRIACYLGLYCEROL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL OUTCOME; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FATTY ACID BLOOD LEVEL; FEMALE; HIGH RISK PATIENT; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; LIVER FIBROSIS; LIVER STIFFNESS; MAGNETIC RESONANCE ELASTOGRAPHY; MALE; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING PROTON DENSITY FAT FRACTION; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; WORK SCHEDULE; ELASTOGRAPHY; LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING;

DOUBLE-BLIND METHOD; ELASTICITY IMAGING TECHNIQUES; HUMANS; LIVER; MAGNETIC RESONANCE IMAGING; NON-ALCOHOLIC FATTY LIVER DISEASE; SITAGLIPTIN PHOSPHATE;

EID: 84969801284     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.04.021     Document Type: Article

References (46)

1. [1] Chalasani, N., Younossi, Z., Lavine, J.E., et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 142 (2012), 1592–1609.
2. [2] Browning, J.D., Szczepaniak, L.S., Dobbins, R., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40 (2004), 1387–1395.
3. [3] Williams, C.D., Stengel, J., Asike, M.I., et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 140 (2011), 124–131.
4. [4] Loomba, R., Sanyal, A.J., The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 10 (2013), 686–690.
5. [5] Wong, V.W., Chu, W.C., Wong, G.L., et al. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut 61 (2012), 409–415.
6. [6] Arulanandan, A., Ang, B., Bettencourt, R., et al. Association between quantity of liver fat and cardiovascular risk in patients with nonalcoholic fatty liver disease independent of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 13 (2015), 1513–1520, e1.
7. [7] Noureddin, M., Rinella, M.E., Nonalcoholic Fatty liver disease, diabetes, obesity, and hepatocellular carcinoma. Clin Liver Dis 19 (2015), 361–379.
8. [8] Loomba, R., Abraham, M., Unalp, A., et al. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology 56 (2012), 943–951.
9. [9] Bazick, J., Donithan, M., Neuschwander-Tetri, B.A., et al. Clinical model for NASH and advanced fibrosis in adult patients with diabetes and NAFLD: guidelines for referral in NAFLD. Diabetes Care 38 (2015), 1347–1355.
10. [10] Idilman, R., Mizrak, D., Corapcioglu, D., et al. Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 28 (2008), 200–208.
11. [11] Loomba, R., Lutchman, G., Kleiner, D.E., et al. Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther 29 (2009), 172–182.
12. [12] Doycheva, I., Loomba, R., Effect of metformin on ballooning degeneration in nonalcoholic steatohepatitis (NASH): when to use metformin in nonalcoholic fatty liver disease (NAFLD). Adv Ther 31 (2014), 30–43.
13. [13] Ratziu, V., Giral, P., Jacqueminet, S., et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 135 (2008), 100–110.
14. [14] Ratziu, V., Charlotte, F., Bernhardt, C., et al. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology 51 (2010), 445–453.
15. [15] Belfort, R., Harrison, S.A., Brown, K., et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355 (2006), 2297–2307.
16. [16] Aithal, G.P., Thomas, J.A., Kaye, P.V., et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 135 (2008), 1176–1184.
17. [17] Sanyal, A.J., Chalasani, N., Kowdley, K.V., et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 362 (2010), 1675–1685.
18. [18] Armstrong, M.J., Gaunt, P., Aithal, G.P., et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 387 (2016), 679–690.
19. [19] Herman, G.A., Bergman, A., Liu, F., et al. Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects. J Clin Pharmacol 46 (2006), 876–886.
20. [20] Ferre, P., Foufelle, F., Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c. Diabetes Obes Metab 12 (2010), 83–92.
21. [21] Tremblay, A.J., Lamarche, B., Deacon, C.F., et al. Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes. Diabetes Obes Metab 13 (2011), 366–373.
22. [22] Monami, M., Lamanna, C., Desideri, C.M., et al. DPP-4 inhibitors and lipids: systematic review and meta-analysis. Adv Ther 29 (2012), 14–25.
23. [23] Giampietro, O., Giampietro, C., Bartola, L.D., et al. Sitagliptin as add-on therapy in insulin deficiency: biomarkers of therapeutic efficacy respond differently in type 1 and type 2 diabetes. Drug Des Devel Ther 7 (2013), 99–104.
24. [24] Iwasaki, T., Tomeno, W., Yoneda, M., et al. Non-alcoholic fatty liver disease adversely affects the glycemic control afforded by sitagliptin. Hepatogastroenterology 59 (2012), 1522–1525.
25. [25] Yilmaz, Y., Yonal, O., Deyneli, O., et al. Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis. Acta Gastroenterol Belg 75 (2012), 240–244.
26. [26] Kim, D., Kim, W.R., Talwalkar, J.A., et al. Advanced fibrosis in nonalcoholic fatty liver disease: noninvasive assessment with MR elastography. Radiology 268 (2013), 411–419.
27. [27] Loomba, R., Wolfson, T., Ang, B., et al. Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study. Hepatology 60 (2014), 1920–1928.
28. [28] Loomba, R., Schork, N., Chen, C.H., et al. Heritability of hepatic fibrosis and steatosis based on a prospective twin study. Gastroenterology 149 (2015), 1784–1793.
29. [29] Loomba, R., Cui, J., Wolfson, T., et al. Novel 3D magnetic resonance elastography for the noninvasive diagnosis of advanced fibrosis in NAFLD: a prospective study. Am J Gastroenterol, 2016, 10.1038/ajg.2016.65 [Epub ahead of print].
30. [30] J. Cui, E. Heba, Hernandez, C., et al. Magnetic resonance elastography is superior to acoustic radiation force impulse for the Diagnosis of fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease: a prospective study. Hepatology 63 (2016), 453–461.
31. [31] Imajo, K., Kessoku, T., Honda, Y., et al. Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography. Gastroenterology 150 (2016), 626–637, e7.
32. [32] Patel, K., Gordon, S.C., Jacobson, I., et al. Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. J Hepatol 41 (2004), 935–942.
33. [33] Zaman, A., Rosen, H.R., Ingram, K., et al. Assessment of FIBROSpect II to detect hepatic fibrosis in chronic hepatitis C patients. Am J Med, 120, 2007, 280, e9–e14.
34. [34] Le, T.A., Chen, J., Changchien, C., et al. Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial. Hepatology 56 (2012), 922–932.
35. [35] Neuschwander-Tetri, B.A., Loomba, R., Sanyal, A.J., et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385 (2015), 956–965.
36. [36] S.C. Lin, E. Heba, Wolfson, T., et al. Noninvasive diagnosis of nonalcoholic fatty liver disease and quantification of liver fat using a new quantitative ultrasound technique. Clin Gastroenterol Hepatol 13 (2015), 1337–1345, e6.
37. [37] Loomba, R., Sirlin, C.B., Ang, B., et al. Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial). Hepatology 61 (2015), 1239–1250.
38. [38] Zarrinpar, A., Gupta, S., Maurya, M.R., et al. Serum microRNAs explain discordance of non-alcoholic fatty liver disease in monozygotic and dizygotic twins: a prospective study. Gut, 2015, 10.1136/gutjnl-2015-309456 [Epub ahead of print].
39. [39] Noureddin, M., Lam, J., Peterson, M.R., et al. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology 58 (2013), 1930–1940.
40. [40] Patel, N.S., Peterson, M.R., Brenner, D.A., et al. Association between novel MRI-estimated pancreatic fat and liver histology-determined steatosis and fibrosis in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 37 (2013), 630–639.
41. [41] Reeder, S.B., Cruite, I., Hamilton, G., et al. Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy. J Magn Reson Imaging, 34, 2011, spcone.
42. [42] Permutt, Z., Le, T.A., Peterson, M.R., et al. Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease – MRI accurately quantifies hepatic steatosis in NAFLD. Aliment Pharmacol Ther 36 (2012), 22–29.
43. [43] Reeder, S.B., Emerging quantitative magnetic resonance imaging biomarkers of hepatic steatosis. Hepatology 58 (2013), 1877–1880.
44. [44] Cui, J., Ang, B., Haufe, W., et al. Comparative diagnostic accuracy of magnetic resonance elastography vs. eight clinical prediction rules for non-invasive diagnosis of advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease: a prospective study. Aliment Pharmacol Ther 41 (2015), 1271–1280.
45. [45] Doycheva, I., Cui, J., Nguyen, P., et al. Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE. Aliment Pharmacol Ther 43 (2016), 83–95.
46. [46] Chen, J., Talwalkar, J.A., Yin, M., et al. Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography. Radiology 259 (2011), 749–756.